LaVoieHealthScience Awarded Best Pharma Product Launch at 2024 PRWeek Healthcare Awards

BOSTON and NEW YORK – May 22, 2024 – LaVoieHealthScience (LHS) is honored to be awarded with the prestigious title of “Best Pharma Product Launch (Non-OTC)” at this year’s PRWeek Healthcare Awards on May 21. This award is for the partnership with Menarini Stemline from the 2023 launch of ORSERDU® (elacestrant) for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

The award-winning product launch, which focused on increasing visibility and on-label education of ORSERDU®, the first oral selective estrogen receptor modulator (SERD), approved for marketing in the US in January 2023. The combined teams’ communication efforts highlight the impactful collaboration between Menarini Stemline and LaVoieHealthScience.

Donna L. LaVoie, President and CEO of LaVoieHealthScience, expressed her gratitude and pride in the teams’ achievement: “We are immensely proud of our team’s hard work and dedication to the ‘why’ behind this important project. This recognition from PRWeek Healthcare Awards underscores our commitment to excellence in healthcare communications and our dedication to improving patient outcomes. Our commercial practice PR account team, both past and present, played an important role in bringing the first endocrine innovation in 20 years, addressing ESR1 mutations, a major unmet need.”

The PRWeek Healthcare Awards is renowned for celebrating the best of the best in healthcare public relations, recognizing firms that drive the industry forward through innovative and creative strategies.

LaVoieHealthScience extends its thanks to the team at Menarini Stemline for entrusting us with the opportunity to be part of such significant and impactful work. This award is a shared success, reflecting the synergy and collaboration between our organizations. Read our case study with Menarini Stemline here.

About LaVoieHealthScience

LaVoieHealthScience partners with health and science emerging and commercial organizations to advance their innovations. The complexity of the business of science, medicine, and technology requires leaders to create a unique voice in a highly regulated industry. We guide leaders using our 20+ years of history with modern perspectives and time-tested results. Our programs include strategic positioning, public relations and marketing, investor relations, corporate communications, and digital and creative services. For more information, please visit lavoiehealthscience.com and connect with us on LinkedIn, X, Facebook.

Agency Contact:

Lisa DeScenza
SVP, Corporate Communications & Investor Relations
(617) 351-0243
ldescenza@lavoiehealthscience.com